Prostate cancer gene therapy: Past experiences and future promise

Cancer and Metastasis Reviews

Volumn 21, Issue 2, 2002, Pages 137-145

  Gardner, Thomas A ^a   Sloan, James ^b   Raikwar, Sudhanshu P ^b   Kao, Chinghai ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Gene therapy; Metastatic; Prostate cancer trials; Transcriptional targeting; Tumor specific promoters

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; MYC PROTEIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN P16; PROTEIN P53; THYMIDINE KINASE; VALACICLOVIR;

ARTICLE; DRUG EFFICACY; DRUG SAFETY; GENE THERAPY; GENE TRANSFER; HUMAN; LIVER DYSFUNCTION; LIVER TOXICITY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; RISK BENEFIT ANALYSIS; SUICIDE GENE THERAPY; THROMBOCYTOPENIA; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM; ANIMAL; FORECASTING; GENETICS; METHODOLOGY; PROSTATE TUMOR; REVIEW;

ANIMALS; FORECASTING; GENE THERAPY; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 0036432858     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020875925685     Document Type: Article

References (20)

1. Jemal A, Thomas A, Murray T, Thun M: Cancer statistics. CA Cancer J Clin 52(1): 23, 2002
2. Gardner TA, Ko S-C, Kao C, Shirakawa T, Cheon J, Gotoh A, Wu T, Sikes RA, Zhau HE, Cui Q, Balian G, Chung LWK: Exploiting stromal-epithial interaction for model development and new strategies of gene therapy for prostate cancer and osteosarcoma metastases. Gene Therapy Mol Biol 2: 41, 1998
3. Koeneman KS, Kao C, Ko SC, Yang L, Wada Y, Kallmes DF, Gillenwater JY, Zhau HE, Chung LW, Gardner TA: Osteocalcin-directed gene therapy for prostate-cancer bone metastasis. World J Urol 18(2): 102, 2000
4. Matsubara S, Wada Y, Gardner TA, Egawa M, Park MS, Hsieh CL, Zhau HE, Kao C, Kamidono S, Gillenwater JY, Chung LW: A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis. Cancer Res 61(16): 6012, 2001
5. Office of Biotechnology Activities' Recombinant DNA and Gene Transfer Web Page, http://www4.od.nih.gov/oba/Rdna.htm
6. Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Lim M, Weber CE, Baccala AA, Goemann MA, Clift SM, Ando DG, Levitsky HI, Cohen LK, Sanda MG, Mulligan RC, Partin AW, Carter HB, Piantadosi S, Marshall FF, Nelson WG: Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 59(20): 5160, 1999
7. Ko SC, Gotoh A, Thalmann GN, Zhau HE, Johnston DA, Zhang WW, Kao C, Chung LW: Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model. Hum Gene Ther 7(14): 1683, 1996
8. Gotoh A, Ko SC, Shirakawa T, Cheon J, Kao C, Miyamoto T, Gardner TA, Ho LJ, Cleutjens CB, Trapman J, Graham FL, Chung LW: Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer. J Urol 160(1): 220, 1998
9. Pang S, Taneja S, Dardashti K, Cohan P, Kaboo R, Sokoloff M, Tso CL, Dekernion JB, Belldegrun AS: Prostate tissue specificity of the prostate-specific antigen promoter isolated from a patient with prostate cancer. Hum Gene Ther 6(11): 1417, 1995
10. Richards CA, Wolberg AS, Huber BE: The transcriptional control region of the human carcinoembryonic antigen gene: DNA sequence and homology studies. DNA Seq 4(3): 185, 1993
11. Huber BE, Richards CA, Austin EA: Virus-directed enzyme/prodrug therapy (VDEPT). Selectively engineering drug sensitivity into tumors. Ann N Y Acad Sci 716: 104, 1994
12. Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR: Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 57(13): 2559, 1997
13. DeWeese TL, van der Poel H, Li S, Mikhak B, Drew R, Goemann M, Hamper U, DeJong R, Detorie N, Rodriguez R, Haulk T, DeMarzo AM, Piantadosi S, Yu DC, Chen Y, Henderson DR, Carducci MA, Nelson WG, Simons JW: A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res 61(20): 7464, 2001
14. Yu DC, Chen Y, Seng M, Dilley J, Henderson DR: The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res 59(17): 4200, 1999
15. Varghese S, Newsome JT, Rabkin SD, McGeagh K, Mahoney D, Nielsen P, Todo T, Martuza RL: Preclinical safety evaluation of G207, a replication-competent herpes simplex virus type 1, inoculated intraprostatically in mice and nonhuman primates. Hum Gene Ther 12(8): 999, 2001
16. Yu D, Chen D, Chiu C, Razmazma B, Chow YH, Pang S: Prostate-specific targeting using PSA promoter-based lentiviral vectors. Cancer Gene Ther 8(9): 628, 2001
17. Herman JR, Adler HL, Aguilar-Cordova E, Rojas-Martinez A, Woo S, Timme TL, Wheeler TM, Thompson TC, Scardino PT: In situ gene therapy for adenocarcinoma of the prostate: A phase I clinical trial. Hum Gene Ther 10(7): 1239, 1999
18. Shalev M, Kadmon D, Teh BS, Butler EB, Aguilar-Cordova E, Thompson TC, Herman JR, Adler HL, Scardino PT, Miles BJ: Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer. J Urol 163(6): 1747, 2000
19. Pantuck AJ, Zisman A, Belldegrun AS: Gene therapy for prostate cancer at the University of California, Los Angeles: Preliminary results and future directions. World J Urol 18(2): 143, 2000
20. Eder JP, Kantoff PW, Roper K, Xu GX, Bubley GJ, Boyden J, Gritz L, Mazzara G, Oh WK, Arlen P, Tsang KY, Panicali D, Schlom J, Kufe DW: A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res 6(5): 1632, 2000